Define Success Before the First Dose

Wishing to feel better is not a goal

Once a man has settled on a formulation, the first dose feels like a foregone conclusion, and that is precisely when the definition of success gets skipped. Testosterone is very good at raising a lab value while leaving the original complaint untouched, and if nothing is written down, the better number quietly becomes the whole point. So before anything is prescribed I put one question on the table: if this treatment improves only a single thing, which one would make it worthwhile?

"I want to feel better" is an honest wish and a useless yardstick. A workable goal anchors a symptom or a function to daily life: starting sex rather than avoiding it, making it through the afternoon without lying down, getting back to the usual walking route, regaining the morning erections that had clearly disappeared. It has to be something he cares about, and concrete enough that months later both of us can tell whether it moved.

Ranking matters too. When libido, erections, muscle, body fat, mood, concentration, sleep, confidence, and longevity all sit at the same level of importance, nearly any mixed outcome can be spun as a partial win. Sexual goals deserve extra precision, because desire, spontaneous erections, reliable erections with a partner, orgasm, and satisfaction with the relationship are connected but distinct, and testosterone does not act on each of them the same way.

Capture the starting point first

The baseline is the picture we will hold every later result against, for benefit and for harm alike. Mine includes the pattern of symptoms, exam findings, properly timed hormone levels, and whatever safety data fit the man's age, history, and chosen route: blood pressure, hematocrit, prostate assessment where it applies, sleep symptoms, fertility intentions, and a full medication list down to over-the-counter products and any hormone from another source.

It also records the rival explanations, the fatigue that started with a new sedating drug, the libido that vanished during a depressive episode, because the response only makes sense in that larger context.

Fertility belongs in the baseline even when the treatment is about symptoms. Prescription testosterone can shut down sperm production, and no man who might want children should learn that afterward. Baseline also means writing down what is already abnormal: an elevated hematocrit, blood pressure out of control, severe untreated sleep apnea, worrisome urinary symptoms, or a prostate finding nobody has evaluated may determine whether treatment starts at all.

The purpose of a target level

A serum testosterone verifies exposure and helps me interpret the response. It is not a grade for masculinity, health, or quality of care.

What follows is my own practice, and I label it that way rather than as a guideline requirement. Once a man is established on therapy I aim for a total testosterone somewhere around 500 to 900 nanograms per deciliter. The goal is not the highest number attainable; it is a physiologic range where he feels better without taking on risk he has no reason to take. I defend the top of that range as firmly as the bottom, because hematocrit, blood pressure, acne, and fluid retention all tend to climb with exposure, and none of those improves a complaint the hormone was never going to address. I will not push a man past that range chasing a symptom that has a different cause.

When the sample is drawn matters as much as what it shows. Pellets, injections, nasal products, and gels each trace a different curve, so I fix the timing of the draw before I interpret the number.

Safety is part of the definition

One improved symptom does not make a treatment a success. If desire comes back while hematocrit rises into worrying territory, blood pressure deteriorates, severe sleep-disordered breathing appears, or fertility plans change, the benefit has to be reweighed against the new cost. That is why the safety domains are named before the first dose: usually hematocrit or hemoglobin, blood pressure, prostate and urinary findings where relevant, effects specific to the formulation, and shifts in sleep, fluid, skin, breast tissue, or mood. Naming them up front makes an inconvenient signal much harder to wave away later.

Set a real review date

A trial with no end point is nearly impossible to interpret. My structured review lands at about six months once treatment is established, and again, that is a habit of mine rather than a guideline rule. A man with a high starting hematocrit, a change in formulation, or a new symptom is seen earlier, and anything urgent never waits for the calendar.

At that review I want three answers. Did the intended outcome improve in a way that matters to him? Was the exposure measured correctly? Has any new safety or burden signal shifted the balance? Continuing, switching formulation, and stopping are all legitimate results. So is a revised diagnosis: when appropriate exposure leaves the target symptom unchanged, the next move is to examine sleep, mood, vascular disease, medications, or relationship strain, not to call him a poor responder.

The trap is the moving goalpost: treatment begins for low desire, desire does not change, a modest gym gain is offered instead, then a reassuring lab, and the original question is never answered. We can decide together whether some new benefit justifies going on, but the original endpoint does not get erased.

Common questions